Defenx Plc (LON:DFX) Hit With Under Review Rating At Beaufort Securities, Is This a Concern?; Sphera Funds Management LTD Cut Cytokinetics (Call) (CYTK) Position

Sphera Funds Management Ltd decreased Cytokinetics Inc (Call) (CYTK) stake by 54.13% reported in 2017Q3 SEC filing. Sphera Funds Management Ltd sold 117,990 shares as Cytokinetics Inc (Call) (CYTK)’s stock rose 26.22%. The Sphera Funds Management Ltd holds 100,000 shares with $1.45 million value, down from 217,990 last quarter. Cytokinetics Inc (Call) now has $522.68 million valuation. The stock decreased 1.02% or $0.1 during the last trading session, reaching $9.7. About 306,132 shares traded. Cytokinetics, Incorporated (NASDAQ:CYTK) has risen 88.33% since January 30, 2017 and is uptrending. It has outperformed by 71.63% the S&P500.

Beaufort Securities reissued their ‘Under Review’ rating on shares of Defenx Plc (LON:DFX) in a research note sent to investors on Tuesday morning.

Among 2 analysts covering Defenx (LON:DFX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Defenx has GBX 205 highest and GBX 170 lowest target. GBX 187.50’s average target is 837.50% above currents GBX 20 stock price. Defenx had 3 analyst reports since January 27, 2016 according to SRatingsIntel. Beaufort Securities maintained Defenx Plc (LON:DFX) rating on Wednesday, January 25. Beaufort Securities has “Buy” rating and GBX 170 target. As per Wednesday, January 27, the company rating was initiated by WH Ireland.

The stock decreased 11.11% or GBX 2.5 during the last trading session, reaching GBX 20. About 41,927 shares traded. Defenx Plc (LON:DFX) has 0.00% since January 30, 2017 and is . It has underperformed by 16.70% the S&P500.

Defenx Plc, a security software company, provides a range of products for the mobile, PC, and network security markets worldwide. The company has market cap of 2.59 million GBP. The firm operates in three divisions: Security, Backup, and Protection. It has a 3.03 P/E ratio. The Security segment offers Security Suite, which includes antivirus, antispyware, firewall, antispam, and Web protection, as wells as privacy service for the protection of personal details; Defenx Antivirus to protect from viruses and malware in real time; and Mobile Security Suite, which includes anti-phishing, anti-spam, anti-theft, and antivirus features, as well as SIM protection safe browsing.

Since August 1, 2017, it had 0 insider buys, and 12 selling transactions for $2.80 million activity. $147,864 worth of stock was sold by McDowell Caryn Gordon on Wednesday, September 6. Shares for $72,957 were sold by Blum Robert I. GAGE L PATRICK sold $70,000 worth of stock or 5,000 shares. On Thursday, August 31 Morgan Bradley Paul sold $1.77 million worth of Cytokinetics, Incorporated (NASDAQ:CYTK) or 118,330 shares. Another trade for 5,000 shares valued at $70,000 was sold by COSTA SANTO J.

Sphera Funds Management Ltd increased Shire Plc (NASDAQ:SHPG) stake by 18,000 shares to 86,500 valued at $13.25M in 2017Q3. It also upped Tesaro Inc (NASDAQ:TSRO) stake by 25,000 shares and now owns 80,000 shares. Vistagen Therapeutics Inc (VSTA) was raised too.

Analysts await Cytokinetics, Incorporated (NASDAQ:CYTK) to report earnings on February, 15. They expect $-0.71 EPS, down 543.75% or $0.87 from last year’s $0.16 per share. After $-0.60 actual EPS reported by Cytokinetics, Incorporated for the previous quarter, Wall Street now forecasts 18.33% negative EPS growth.

Investors sentiment decreased to 1.39 in Q3 2017. Its down 1.55, from 2.94 in 2017Q2. It turned negative, as 16 investors sold CYTK shares while 30 reduced holdings. 21 funds opened positions while 43 raised stakes. 39.12 million shares or 3.53% more from 37.79 million shares in 2017Q2 were reported. Citadel Advsrs Lc has invested 0.01% in Cytokinetics, Incorporated (NASDAQ:CYTK). Price T Rowe Md has 425,258 shares for 0% of their portfolio. Essex Mgmt Lc reported 0.16% in Cytokinetics, Incorporated (NASDAQ:CYTK). Barclays Public Limited Company holds 15,503 shares. Granite Inv Prtn Ltd Liability Com reported 39,732 shares or 0.04% of all its holdings. Wells Fargo & Company Mn accumulated 50,523 shares. Geode Capital Mngmt Limited Co holds 0% or 421,735 shares. The North Carolina-based Piedmont Inv Advsr Limited Liability Corp has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Nelson Van Denburg & Campbell Wealth Mngmt Gru holds 145 shares or 0% of its portfolio. Cornerstone Mgmt Co has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Proshare Advsrs Lc reported 34,065 shares stake. Howe & Rusling stated it has 167 shares. Sg Americas Secs Lc, a New York-based fund reported 9,360 shares. Moreover, Goldman Sachs Inc has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 344,566 shares. Principal Financial has invested 0.01% in Cytokinetics, Incorporated (NASDAQ:CYTK).

Among 12 analysts covering Cytokinetics (NASDAQ:CYTK), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Cytokinetics has $2600 highest and $13.0 lowest target. $19.67’s average target is 102.78% above currents $9.7 stock price. Cytokinetics had 22 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Friday, October 27. The rating was maintained by TH Capital on Monday, November 9 with “Buy”. On Friday, September 15 the stock rating was maintained by Needham with “Buy”. Morgan Stanley maintained the stock with “Overweight” rating in Friday, October 6 report. Needham maintained Cytokinetics, Incorporated (NASDAQ:CYTK) on Wednesday, July 27 with “Buy” rating. The company was maintained on Thursday, August 3 by Cowen & Co. Piper Jaffray maintained the shares of CYTK in report on Tuesday, November 21 with “Buy” rating. On Monday, November 9 the stock rating was maintained by Roth Capital with “Buy”. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. Morgan Stanley maintained Cytokinetics, Incorporated (NASDAQ:CYTK) rating on Wednesday, November 22. Morgan Stanley has “Buy” rating and $17.0 target.